E-site drug specificity of the human pathogen <i>Candida albicans</i> ribosome.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35613268.
- Also identified by DOI 10.1126/sciadv.abn1062 and PMC identifier 9132455.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>Candida albicans</i> is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E-transfer RNA binding site of the ribosome. Because of lack of structural information, it is neither possible to understand the nature of the resistance nor to develop novel inhibitors. To overcome this issue, we determined the structure of the vacant <i>C. albicans</i> 80<i>S</i> ribosome at 2.3 angstroms and its complexes with bound inhibitors at resolutions better than 2.9 angstroms using cryo-electron microscopy. Our structures reveal how a change in a conserved amino acid in ribosomal protein eL42 explains CHX resistance in <i>C. albicans</i> and forms a basis for further antifungal drug development.
Medical subject headings
- Antifungal Agents
- Candida albicans